Kyowa Kirin Co. Ltd (KYKOF) fair value: what the stock is really worth
As of Nov 18, 2026: fair value (intrinsic value) of Kyowa Kirin Co. Ltd stock $14.22, price $16.20, that is 12.2% below the price, quality 65 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Kyowa Kirin Co. Ltd
KYKOF · USExpensive (fair value 12% below the price) and price moving sideways, but solid company: meets 1 of 3 rules.
Main risks:
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $10.17 – $30.81 · fair‑value band $10.99 – $19.31 · the $16.20 price screens above the $14.22 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Kyowa Kirin Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally.
Show moreShow less
The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis.
It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia.
It has a partnership with La Jolla Institute for Immunology for research in disease areas; AstraZeneca for severe asthma treatment; and AMGEN for therapeutic drugs development. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in July 2019.
Kyowa Kirin Co., Ltd. was incorporated in 1949 and is headquartered in Chiyoda, Japan. The company operates as a subsidiary of Kirin Holdings Company, Limited.
Stock analysis
Kyowa Kirin Co. Ltd (KYKOF) currently trades at $16.20, while our model-based Fair Value estimate is $14.22, 12% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $20.69 per share, and 11 of the 24 models we run sit above the $16.20 price.
Bear case: the Asset-Based group reads lowest at $3.34, and 13 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: $10.99 (bear) to $19.31 (bull), the price of $16.20 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Kyowa Kirin Co. Ltd reported revenue of ¥497B in FY2025 versus ¥352B in FY2021, a compound +9.0%/yr. Reported net income was ¥67.1B in FY2025, compounding +6.4%/yr from FY2021.
Key figures
Market cap $8.5B Mid · P/E ratio 16.0 · P/S ratio 2.16 · EPS (TTM) $1.01 · Dividend yield 2.6% · Net margin 13.5% · Return on equity 9.8% · Return on assets (EBIT) 8.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 59 out of 100 (low confidence).
What moves the price
The share trades about 10% below its 52-week high and 32% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −12%, KYKOF screens cheaper than that median.
Fair Value models
All 24 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
KYKOF screens overvalued: fair value 12% below the price. Compare with Merck KGaA →
Recent news
- Kyowa Kirin (TSE:4151) Stock Looks Cheap On Cash Flow Estimates
- Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
- Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma
Compare Kyowa Kirin Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Net margin by industry
- P/B ratio by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $85.57 | $113.53 | +33% | vs KYKOF |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥46.88 | ¥52.43 | +12% | vs KYKOF |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,900 | ₹1,983 | +4% | vs KYKOF |
| Haleon plc HLN | $9.08 | $8.47 | −7% | vs KYKOF |
| Merck KGaA MRK | €148.40 | €108.83 | −27% | vs KYKOF |
| Galderma Group GALD | CHF 184.70 | CHF 112.46 | −39% | vs KYKOF |
| Takeda Pharmaceutical Company TAK | $21.27 | $11.23 | −47% | vs KYKOF |
| Sandoz Group SDZ | CHF 81.24 | CHF 41.06 | −49% | vs KYKOF |
| Teva Pharmaceutical Industries Limited TEVA | $42.23 | $20.74 | −51% | vs KYKOF |
| Divi's Laboratories Limited DIVISLAB | ₹11,178 | ₹1,567 | −86% | vs KYKOF |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Kyowa Kirin Co. Ltd (KYKOF) overvalued or undervalued?
What is the fair value of KYKOF?
What is the quality score of KYKOF?
What is the price target for Kyowa Kirin Co. Ltd (KYKOF)?
What is the Kyowa Kirin Co. Ltd stock forecast for 2026?
What is the revenue of Kyowa Kirin Co. Ltd (KYKOF)?
Does Kyowa Kirin Co. Ltd pay a dividend?
How much is the dividend of Kyowa Kirin Co. Ltd (KYKOF) and when is the ex-dividend date?
What growth is priced into Kyowa Kirin Co. Ltd (KYKOF)?
What discount rate (WACC) does the fair value of KYKOF use?
What is a reverse DCF?
How much growth has Kyowa Kirin Co. Ltd (KYKOF) delivered so far?
How fast is the sector of Kyowa Kirin Co. Ltd (KYKOF) growing?
What is the free cash flow yield of Kyowa Kirin Co. Ltd (KYKOF)?
What is the intrinsic value of Kyowa Kirin Co. Ltd (KYKOF)?
Is Kyowa Kirin Co. Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of KYKOF?
How much is Kyowa Kirin Co. Ltd worth?
What do the bullish and bearish scenarios say about KYKOF?
What is the P/E ratio of KYKOF?
What is the PEG ratio of KYKOF?
How solid is the balance sheet of Kyowa Kirin Co. Ltd (KYKOF)?
How far is KYKOF from its 52-week high?
Which stocks are comparable to Kyowa Kirin Co. Ltd?
Is Kyowa Kirin Co. Ltd stock attractive at the current price?
How is the fair value of KYKOF calculated?
Is it still worth investing in stocks now?
What is the share price of Kyowa Kirin Co. Ltd (KYKOF)?
What should I pay attention to with Kyowa Kirin Co. Ltd right now?
Where does the earnings growth of Kyowa Kirin Co. Ltd (KYKOF) come from?
Key figures of Kyowa Kirin Co. Ltd
How large is the market capitalisation of Kyowa Kirin Co. Ltd (KYKOF)?
What is the P/S ratio of Kyowa Kirin Co. Ltd (KYKOF)?
What are the earnings per share of Kyowa Kirin Co. Ltd (KYKOF)?
What is the dividend yield of Kyowa Kirin Co. Ltd (KYKOF)?
What is the net margin of Kyowa Kirin Co. Ltd (KYKOF)?
What is the return on equity of Kyowa Kirin Co. Ltd (KYKOF)?
What is the EBIT return on assets of Kyowa Kirin Co. Ltd (KYKOF)?
What is the operating margin of Kyowa Kirin Co. Ltd (KYKOF)?
How fast is revenue growing at Kyowa Kirin Co. Ltd (KYKOF)?
How fast are earnings growing at Kyowa Kirin Co. Ltd (KYKOF)?
How much net cash does Kyowa Kirin Co. Ltd (KYKOF) hold?
Watch Kyowa Kirin Co. Ltd in the live analysis
One click puts Kyowa Kirin Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.